Review




Structured Review

BioIVT Inc peripheral blood cd4 + t lymphocytes
C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or <t>cynomolgus</t> monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
Peripheral Blood Cd4 + T Lymphocytes, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peripheral blood cd4 + t lymphocytes/product/BioIVT Inc
Average 90 stars, based on 1 article reviews
peripheral blood cd4 + t lymphocytes - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents"

Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

Journal: Cancer Immunology Research

doi: 10.1158/2326-6066.CIR-21-0031

C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
Figure Legend Snippet: C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

Techniques Used: Blocking Assay, Enzyme-linked Immunosorbent Assay, Incubation, Recombinant, Concentration Assay, Binding Assay, Control



Similar Products

90
BioIVT Inc peripheral blood cd4 + t lymphocytes
C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or <t>cynomolgus</t> monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.
Peripheral Blood Cd4 + T Lymphocytes, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peripheral blood cd4 + t lymphocytes/product/BioIVT Inc
Average 90 stars, based on 1 article reviews
peripheral blood cd4 + t lymphocytes - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

Journal: Cancer Immunology Research

Article Title: Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

doi: 10.1158/2326-6066.CIR-21-0031

Figure Lengend Snippet: C5H9v2 mAb is a high-affinity blocker of PD-L1 and can potentiate T-cell responses. A, The capacity of C5H9v2 hIgG4 mAb to bind and block immobilized PD-L1 was evaluated in an ELISA format. Serial dilutions of C5H9v2 mAb were incubated with recombinant plate-bound PD-L1-Fc fusion protein of human, mouse, rat, or cynomolgus monkey origin. Bound antibody was detected using an anti-human HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. Serial dilutions of C5H9v2 mAb were added to wells containing biotinylated hPD-1 ( B ) or hB7-1 (CD80; C ) protein and plate-bound PD-L1-Fc to measure blocking capacity. The binding of hPD-1 or hB7-1 to PD-L1 was detected using a streptavidin–HRP conjugate. Data shown are representative of 3 independent experiments. D, Blockade of PD-L1 by C5H9v2 mAb enhanced IFNγ production in a CMV recall assay. CMV-positive hPBMCs were plated at 350,000 cells/well in media containing serial dilutions of C5H9v2 mAb or isotype control and stimulated with 4 μg/mL CMV lysate for 4 days, at which point IFNγ was measured in the supernatants by ELISA. Data shown are representative response from one donor ( n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance; Cyno, cynomolgus monkey; hB7-1, human B7-1; hPBMC, human peripheral blood mononuclear cell.

Article Snippet: Binding of hPD-L1 mAb (C5H9v2), CX-072 Pb-Tx, and preactivated CX-072 Pb-Tx to PD-L1–positive cells of human (SAS human cell line), mouse (MC38 mouse cell line), rat (Sprague Dawley rat peripheral blood CD4 + T lymphocytes, BioIVT, catalog #RATWBLIHPO-M), and cynomolgus monkey (peripheral blood CD4 + T lymphocytes, BioIVT, catalog #CYNWBLIHP-M) origin was evaluated by flow cytometry.

Techniques: Blocking Assay, Enzyme-linked Immunosorbent Assay, Incubation, Recombinant, Concentration Assay, Binding Assay, Control